RENVELA

Drug SANOFI-AVENTIS U.S. LLC
Total Payments
$158,080
Transactions
2,288
Doctors
1,251
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2019 $25,664 8 1
2018 $266.62 14 14
2017 $132,149 2,266 1,246

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79,829 10 50.5%
Food and Beverage $40,183 2,244 25.4%
Travel and Lodging $27,238 24 17.2%
Unspecified $5,498 7 3.5%
Consulting Fee $5,332 3 3.4%

Payments by Type

General
$152,582
2,281 transactions
Research
$5,498
7 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease GENZYME CORPORATION $5,498 7

Top Doctors Receiving Payments for RENVELA — Page 3

Doctor Specialty Location Total Records
, MD Nephrology Livonia, MI $89.09 4
, MD Nephrology Philadelphia, PA $89.06 4
, M.D Nephrology Orangeburg, SC $88.65 6
Dionicio Alvarez Nephrology El Paso, TX $87.37 5
, M.D Nephrology South Miami, FL $87.27 5
, MD Nephrology Miami, FL $86.75 5
, MD Nephrology Bellmore, NY $86.51 4
, M.D Specialist Monroe, NJ $85.64 4
, MD Nephrology Exton, PA $85.62 4
, MD Nephrology New York, NY $85.35 4
, M.D Specialist Houston, TX $85.26 4
, MD Nephrology Long Branch, NJ $85.07 4
, DO Nephrology Brick, NJ $84.56 4
, MD Nephrology South Miami, FL $84.43 5
, M.D Nephrology Murfreesboro, TN $84.43 4
, M.D Student in an Organized Health Care Education/Training Program Neptune, NJ $83.21 4
, MD Internal Medicine Trenton, NJ $83.21 4
, M.D Nephrology Memphis, TN $82.89 5
, M.D Nephrology Riverhead, NY $78.86 4
, M.D Nephrology San Jose, CA $78.24 4
, MD Internal Medicine Columbus, OH $76.13 4
, M.D Nephrology Kettering, OH $76.04 5
, M.D Internal Medicine Richland, WA $75.96 5
, MD Nephrology San Jose, CA $75.50 4
, M.D Nephrology Lawrence, MA $74.17 4

About RENVELA

RENVELA is a drug associated with $158,080 in payments to 1,251 healthcare providers, recorded across 2,288 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.

Payment data is available from 2017 to 2019. In 2019, $25,664 was paid across 8 transactions to 1 doctors.

The most common payment nature for RENVELA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,829, 50.5% of total).

RENVELA is associated with 1 research study, including "Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease" ($5,498).